Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print      Mail a friend

Tuesday 11 December, 2018

C4X Discovery

2018 Annual Report

RNS Number : 1270K
C4X Discovery Holdings PLC
11 December 2018
 

 

 

C4X Discovery Holdings plc

(C4XD, C4X Discovery or the Company)

 

2018 Annual Report

 

11 December 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that the Annual Report and Financial Statements for the year ended 31 July 2018, has been published and sent to shareholders.

 

A copy of the 2018 Annual Report can be viewed on, and downloaded from, the Company's website at https://www.c4xdiscovery.com.

-ENDS-

 

For further information, please contact:

C4X Discovery Holdings plc                                                                                                    +44 (0)7801 865 803

Clive Dix, Chief Executive Officer                                                                                                                                   

 

Panmure Gordon (UK) Limited (NOMAD and Broker)                                                      +44 (0)20 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)             

James Stearns (Corporate Broking)                                                                        

                                                                                 

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal                                                                +44 (0)203 709 5700

 

About C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ACSUASARWSAUAAA

a d v e r t i s e m e n t